Hexarelin is a GH secretague peptide which is similar to GHRP-6. Both of these are used to trigger the natural release of growth hormone in animals: research indicates that hexarelin could have a future in addressing conditions that stem from a deficiency of growth hormone in the body. Unlike similar peptides, hexarelin does not appear to boost the appetite in animals that are exposed to these chemicals. It is also not capable of spiking ghrelin levels that can increase gastric emptying.
The effects of hexarelin are very similar to those of synthetic growth hormone, given its role in triggering natural growth hormone in animals. This can lead to an increase in muscle fibers, increase in strength, and enlargement of existing muscle fibers, protection, healing and joint rejuvenation in animals. Research is ongoing regarding how these applications can affect an animal long-term as well as any side effects that can stem from applying this chemical to animal tissue.
GH Releasing Activity
Studies regarding the effectiveness of growth hormone releasing properties of synthetic chemicals designed to elicit a GHRP analog release was studied, including the effects of hexarelin, GHRP-1, GHRP-2 and GHRP-6.
Studies performed in conscious rats that were 10 days old involved applying hexarelin to determine the effects. This resulted in an active stimulation of growth hormone secretions.
Anesthetized male rates were administered hexarelin or GHRP-6 to see which would cause peak growth hormone levels within 10 minutes.
Throughout multiple trials both of these peptides produced a similar growth hormone response.
The growth hormone response to hexarelin created a longer lasting growth hormone response. This suggests that hexarelin may be more effective in acting as a growth hormone release agent: this chemical may have potential in assisting with diagnostics or therapeutic settings in the future.
GH Independent Cardioprotective Effects
Induction of a selective growth hormone deficiency a rat exacerbates during cardiac dysfunction that has been induced during experiminetl ischemia and reperfusion was performed on an explanted heart.
Short term applications of hexarelin were found to revert this effect, as did applications of synthetic growth hormone.
In order to fully understand how these chemicals acted on or protected heart effects, hexarelin and growth hormone applications were compared in hypophysectomized rats.
Hexarelin was applied for 7 days to prevent the exacerbation of the ischemia reperfusion damage caused to the heart. This demonstrated that hexarelin can increase diastolic pressure and left ventricular which released creatine kinase.
Applications of growth hormone produced similar results to hexarelin but this chemical does not bind to the heart to prevent cardiac damage. Therefore ischemia reperfusion is not likely to be improved by applying growth hormone.
While multiple studies have indicated that applying growth hormone to rats after a myocardial infarction can improve cardiac performance, the effects of hexarelin are still being compared for their results.
After four weeks of ligation using hexarelin on the left artery of male rats, a transthoracic echocardiography was performed. Growth hormone was found to increase weight gain and stroke volume but not hexarelin.
Hexarelin is found to improve cardiac function of rats with peripheral resistance in a similar manner as growth hormone. The specific mechanisms that cause this reaction are still unclear. Scientists speculate that growth hormone effects hexarelin which in turn creates the effects seen on the cardiovascular system.
Growth hormone increase from the application of hexarelin can lead to a reduction of fat tissue because this chemical can increase the circulation of growth hormone. This, in turn, will increase the presence of IGF-1 in the liver. This reaction causes muscle growth but can also be used to increase energy levels and metabolism function.